Knight Therapeutics Launches WYNZORA® in Canada, Expanding Psoriasis Treatment Portfolio — Knight Therapeutics Inc.

Event summary

Knight Therapeutics launched WYNZORA® in Canada on August 20, 2026, a topical treatment for psoriasis vulgaris in adults and adolescents aged 12 and older.
The launch follows Health Canada approval in December 2025 and Knight's acquisition of Paladin Pharma's assets in June 2025.
WYNZORA® combines calcipotriol and betamethasone dipropionate in an aqueous cream formulation enabled by MC2's PAD Technology™.
Clinical trials demonstrated WYNZORA®'s superiority over vehicle and non-inferiority to existing treatments.

The big picture

Knight Therapeutics' launch of WYNZORA® in Canada marks a strategic expansion of its dermatology portfolio, targeting a chronic condition affecting approximately 1 million Canadians. The acquisition of Paladin Pharma's assets and subsequent regulatory approvals position Knight to capitalize on the growing demand for innovative psoriasis treatments. The company's focus on pan-American markets (excluding the U.S.) aligns with broader industry trends of regional specialization in pharmaceutical commercialization.

What we're watching

Market Penetration: How quickly WYNZORA® gains market share in Canada's psoriasis treatment landscape, competing with established therapies.
Commercial Execution: Whether Knight can effectively leverage its existing Canadian platform to drive WYNZORA®'s adoption among healthcare providers and patients.
Regulatory Expansion: The pace at which Knight pursues regulatory approvals for WYNZORA® in other Latin American markets, following its success in Canada.